In a significant development for diabetes treatment, the first generic version of a GLP-1 medication has become available. Launched on June 25, the generic Victoza is expected to enhance accessibility and affordability for patients managing Type 2 diabetes and weight loss.
Manufactured by Novo Nordisk and marketed by Teva Pharmaceuticals, the new generic form of Victoza features liraglutide, the same active ingredient as the brand-name version. This launch addresses a growing demand for cost-effective diabetes treatments amid increasing shortages and high prices of popular medications like Ozempic and Wegovy.
“By introducing an authorized generic for Victoza (liraglutide injection 1.8mg), we are offering another viable option for treating Type 2 diabetes,” stated Ernie Richardsen, Senior Vice President of U.S. Commercial Generics at Teva. The generic version mirrors the brand-name medication in efficacy but comes at a reduced price, making it a more accessible choice for many patients.
Alyssa Billingsley, Senior Director of Pharmacy Content at GoodRx, explained that while the new generic is identical to Victoza in terms of its composition and therapeutic effects, it is sold at a lower cost due to the absence of brand-name labeling. This price reduction could make a significant difference for individuals facing financial barriers to accessing these essential medications.
The introduction of this generic is seen as a positive step towards making GLP-1 agonists more affordable. These medications, which include semaglutide-based drugs like Ozempic and Wegovy, have been praised for their effectiveness in managing diabetes and promoting weight loss. However, their high costs have often limited their accessibility.
Despite the benefits, Billingsley noted that insurance coverage may still favor the brand-name Victoza over the generic option, so patients should verify with their insurance providers to understand their coverage and potential costs.
Dr. Brett Osborn, a Florida neurologist and longevity expert, commended the launch of the generic GLP-1, highlighting its importance for patients with chronic conditions. “For those requiring long-term medication to manage diabetes and prevent related complications, the lower price of the generic version is excellent news,” Osborn remarked.
While the new generic Victoza provides a valuable alternative, it differs from other GLP-1 medications like Ozempic and Wegovy in several ways. Notably, Victoza, with liraglutide as its active ingredient, requires daily dosing due to its shorter half-life, whereas semaglutides like Ozempic are administered weekly.
Both liraglutide and semaglutide support similar functions—appetite suppression and insulin secretion—but have different dosing schedules and side effect profiles. Common side effects of liraglutide include nausea, vomiting, diarrhea, and constipation, though more serious effects are possible.
Overall, the introduction of the generic Victoza represents a significant advancement in diabetes treatment, offering a more affordable option for patients and contributing to efforts to address the ongoing challenges in medication accessibility.
Related topics:
San Antonio Nonprofits Collaborate with ADA to Promote Diabetes Prevention Among Kids
Olive Compound Shows Potential Against Obesity and Type 2 Diabetes
Tailored Exercise Programs Offer Hope for Type 2 Diabetics Battling Long COVID
